DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. [electronic resource]
Producer: 20200608Description: 5005-5019 p. digitalISSN:- 1558-8238
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Azacitidine -- pharmacology
- Cell Line, Tumor
- DNA Methylation
- Dendritic Cells -- metabolism
- Drug Delivery Systems
- Female
- Hematologic Neoplasms -- drug therapy
- Humans
- Interleukin-3 Receptor alpha Subunit -- metabolism
- Leukemia, Myeloid, Acute -- drug therapy
- Male
- Mice
- Mice, Nude
- Minor Histocompatibility Antigens -- metabolism
- Neoplasm Proteins -- metabolism
- Recombinant Fusion Proteins -- pharmacology
- Tumor Suppressor Proteins -- metabolism
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.